Nonracemic mixtures and uses thereof
First Claim
Patent Images
1. A composition comprising:
- (R)-(+)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base; and
(S)-(−
)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base;
wherein the combined amount of (R)-(+)-amisulpride and (S)-(−
)-amisulpride, or pharmaceutically acceptable salts thereof, is about 200 mg to about 600 mg by weight of free base; and
wherein the enantiomeric ratio of (R)-(+)-amisulpride to (S)-(−
)-amisulpride in the composition is about 85;
15 by weight of free base.
1 Assignment
0 Petitions
Accused Products
Abstract
Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are various formulations thereof, including, but not limited to, formulations employing polymorphs of enantiomeric amisulpride.
60 Citations
6 Claims
-
1. A composition comprising:
-
(R)-(+)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base; and (S)-(−
)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base;wherein the combined amount of (R)-(+)-amisulpride and (S)-(−
)-amisulpride, or pharmaceutically acceptable salts thereof, is about 200 mg to about 600 mg by weight of free base; andwherein the enantiomeric ratio of (R)-(+)-amisulpride to (S)-(−
)-amisulpride in the composition is about 85;
15 by weight of free base. - View Dependent Claims (2)
-
-
3. A composition comprising:
-
(R)-(+)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base; and (S)-(−
)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base;wherein the combined amount of (R)-(+)-amisulpride and (S)-(−
)-amisulpride, or pharmaceutically acceptable salts thereof, is about 200 mg to about 400 mg by weight of free base; andwherein the enantiomeric ratio of (R)-(+)-amisulpride to (S)-(−
)-amisulpride in the composition is about 85;
15 by weight of free base. - View Dependent Claims (4, 5, 6)
-
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeSunovion Pharmaceuticals Inc. (Sumitomo Chemical Company Limited)
-
Original AssigneeSunovion Pharmaceuticals Inc. (Sumitomo Chemical Company Limited)
-
InventorsHopkins, Seth Cabot, Koblan, Kenneth Stephen, Snoonian, John R., Wilkinson, Harold Scott
-
Primary Examiner(s)Badio, Barbara P
-
Application NumberUS16/452,880Publication NumberTime in Patent Office251 DaysField of SearchUS Class CurrentCPC Class CodesA61K 31/40 having five-membered rings ...A61P 25/24 Antidepressants
